Study guide
2.4 COPD, Bronchial Asthma & Pulmonary Embolism
Combined Medical Services Examination UPSC CMS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Logistics & Pattern
1.1 UPSC CMS Examination Overview & Eligibility 1.2 Two-Paper Written Exam Pattern & Negative Marking 1.3 Personality Test, Service Allocation & Career Paths
2 Chapter 2: General Medicine - Cardiology & Respiratory
2.1 Coronary Artery Disease & Acute Myocardial Infarction 2.2 Heart Failure & Cardiac Arrhythmias 2.3 Community-Acquired Pneumonia & Pulmonary Tuberculosis 2.4 COPD, Bronchial Asthma & Pulmonary Embolism
3 Chapter 3: General Medicine - Gastroenterology & Hepatology
3.1 Peptic Ulcer Disease & Upper GI Bleeding 3.2 Liver Cirrhosis & Portal Hypertension 3.3 Acute & Chronic Viral Hepatitis & Pancreatitis 3.4 Inflammatory Bowel Disease & Malabsorption Syndromes
4 Chapter 4: General Medicine - Nephrology & Endocrinology
4.1 Acute Kidney Injury & Chronic Kidney Disease 4.2 Glomerulonephritis, Nephrotic Syndrome & Electrolyte Imbalances 4.3 Diabetes Mellitus: Diagnosis, Complications & Management 4.4 Thyroid Disorders & Adrenal Gland Dysfunction
5 Chapter 5: General Medicine - Neurology, Haematology & Infection
5.1 Cerebrovascular Accidents (Stroke) & Epilepsy 5.2 Approach to Anaemia: Microcytic, Megaloblastic & Haemolytic 5.3 Acute & Chronic Leukaemias and Lymphomas 5.4 Tropical & Endemic Infections: Malaria, Typhoid & Dengue
6 Chapter 6: General Medicine - Emergency Medicine & Toxicology
6.1 Acute Anaphylaxis, Sepsis & Cardiopulmonary Resuscitation 6.2 Organophosphate, Paracetamol & Snakebite Toxicology 6.3 Common Dermatological & Psychiatric Manifestations in Internal Medicine 6.4 Musculoskeletal System & Adult Rheumatology
7 Chapter 7: Paediatrics - Neonatology & Child Growth
7.1 Newborn Care, Neonatal Resuscitation & APGAR Score 7.2 Prematurity, Low Birth Weight & Neonatal Jaundice 7.3 Infant & Child Growth & Developmental Milestones
8 Chapter 8: Paediatrics - Child Health & Nutrition
8.1 Protein-Energy Malnutrition (PEM) & Micronutrient Deficiencies 8.2 Universal Immunization Programme (UIP) & Child Vaccines 8.3 Pediatric Diarrhoea, Dehydration & Respiratory Emergencies 8.4 Birth Defects, Genetic Counseling, Autism & Paediatric Accidents/Poisoning
9 Chapter 9: Surgery - General Surgery, Wounds & Shock
9.1 Wound Healing, Surgical Site Infections & Gas Gangrene 9.2 Pathophysiology of Shock & Perioperative Fluid Therapy 9.3 Acute Abdomen: Appendicitis, Peritonitis & Intestinal Obstruction 9.4 Classification, Resuscitation & Management of Thermal Burns 9.5 Medicolegal & Ethical Issues in Surgery
10 Chapter 10: Surgery - Surgical Specialties I
10.1 Inguinal, Femoral & Ventral Hernias 10.2 Benign Breast Diseases & Breast Carcinoma 10.3 Solitary Thyroid Nodule & Thyroid Carcinoma 10.4 Benign Prostatic Hyperplasia & Renal Calculi
11 Chapter 11: Surgery - ENT, Orthopaedics & Anaesthesia
11.1 Acute Otitis Media, Tonsillitis & Epistaxis 11.2 Cataract, Glaucoma & Red Eye Emergencies 11.3 Principles of Fracture Management & Common Dislocation 11.4 Principles of Local, Regional & General Anaesthesia 11.5 Neurosurgery: Raised ICP, Head Injury & CNS Lesions 11.6 Thoracic Surgery: Chest Trauma, Pleural & Lung Disease
12 Chapter 12: Obstetrics - Antenatal Care & Complications
12.1 Antenatal Care, Maternal Nutrition & Fetal Assessment 12.2 Preeclampsia, Eclampsia & Gestational Hypertension 12.3 Antepartum Haemorrhage: Placenta Previa & Abruptio Placentae 12.4 Anemia in Pregnancy & Gestational Diabetes Mellitus 12.5 Spontaneous & Recurrent Abortion: Recognition & Management
13 Chapter 13: Obstetrics & Gynaecology - Labor & PPH
13.1 Normal Labor Mechanisms & Partograph Monitoring 13.2 Malpresentations, Breech & Obstructed Labor 13.3 Postpartum Haemorrhage (PPH) Causes & Management 13.4 Puerperal Sepsis & Postnatal Maternal Care
14 Chapter 14: Gynaecology & Family Planning
14.1 Abnormal Uterine Bleeding & Uterine Fibroids 14.2 Cervical Screening (Pap Smear) & Pelvic Inflammatory Disease 14.3 Temporary & Permanent Contraceptive Methods in India 14.4 Medical Termination of Pregnancy (MTP): Law & Methods
15 Chapter 15: PSM - Epidemiology & Biostatistics
15.1 Principles of Epidemiology & Disease Transmission 15.2 Observational & Experimental Epidemiological Study Designs 15.3 Evaluation of Screening Tests: Sensitivity, Specificity & Predictive Value 15.4 Biostatistics: Sampling, Central Tendency & Significance Testing
16 Chapter 16: PSM - Disease Epidemiology & Programmes
16.1 Epidemiology & Control of TB, Malaria & Dengue 16.2 National Tuberculosis Elimination Programme & NVBDCP 16.3 Epidemiology of Hypertension, Diabetes & Cancer in India 16.4 Cold Chain Management & Vaccine Logistics in India 16.5 Genetics and Health: Inheritance, Screening & Counseling
17 Chapter 17: PSM - Health Planning & Environmental Health
17.1 Demography, Fertility Rates & Family Welfare Indicators 17.2 Safe Water Supply, Waste Disposal & Air Pollution 17.3 Occupational Health Hazards & Pneumoconioses 17.4 Health Care Delivery System, Ayushman Bharat & National Health Mission 17.5 International Health: WHO, Global Agencies & SDG 3 17.6 Medical Sociology & Health Education
2.4 COPD, Bronchial Asthma & Pulmonary Embolism
Key Takeaways Explain This Topic AI
Spirometry is essential for diagnosis: COPD is defined by a post-bronchodilator FEV1/FVC ratio <0.70 (persistent airflow limitation), whereas Asthma shows significant bronchodilator reversibility (increase in FEV1 by >12% and >200 mL).
Acute severe COPD exacerbations are managed with inhaled bronchodilators, systemic corticosteroids (oral Prednisolone 40 mg daily for 5 days), and targeted oxygen therapy maintaining SpO2 88-92% to avoid abolishing the hypoxic drive to breathe.
According to GINA guidelines, Asthma therapy prioritizes Anti-Inflammatory Reliever (AIR / MART) therapy using low-dose Inhaled Corticosteroid (ICS)-Formoterol across all steps, while acute severe asthma red flags include a normal or elevated PaCO2 indicating respiratory muscle fatigue and impending failure.
Pulmonary Embolism (PE) risk is stratified using the Wells criteria: low-probability patients undergo D-dimer testing (high negative predictive value), while high-probability patients require CT Pulmonary Angiography (CTPA), with immediate thrombolysis indicated for hemodynamically unstable massive PE.
Last updated: July 2026
- COPD, Bronchial Asthma & Pulmonary Embolism
- 1. Obstructive Airway Disease: COPD vs Asthma Differential
Chronic Obstructive Pulmonary Disease (COPD) and Bronchial Asthma are characterized by airflow limitation, but differ fundamentally in etiology, inflammation, and reversibility.
Feature Chronic Obstructive Pulmonary Disease (COPD) Bronchial Asthma
Primary Age of Onset Typically > 40 years >40 \text{ years} > 40 years Usually onset in childhood or early adulthood
Etiology / Risk Factors Tobacco smoking ( > 90 % >90\% > 90% ), biomass fuel smoke, α 1 \alpha_1 α 1 -antitrypsin deficiency Genetic predisposition, atopy, environmental allergens, occupational exposures
Inflammatory Profile Neutrophilic inflammation (CD8+ T-cells, macrophages) Eosinophilic inflammation (CD4+ Th2 cells, IgE, Mast cells)
Spirometry Definition Post-bronchodilator F E V 1 / F V C < 0.70 FEV_1/FVC < 0.70 FE V 1 / F V C < 0.70 (Fixed/Irreversible airflow limitation) Post-bronchodilator F E V 1 FEV_1 FE V 1 increase > 12 % >12\% > 12% AND > 200 mL >200 \text{ mL} > 200 mL (Reversible)
Course & Progression Progressive, relentless decline in lung function Variable symptoms, wide nocturnal variations, symptom-free intervals
High-Yield Clinical Entity ( α 1 \alpha_1 α 1 -Antitrypsin Deficiency): Consider α 1 \alpha_1 α 1 -antitrypsin ( α 1 \alpha_1 α 1 -AT) deficiency in young non-smokers ( < 45 years <45 \text{ years} < 45 years ) presenting with COPD or liver cirrhosis. It causes panacinar emphysema predominantly affecting the lower lobes of the lung (unlike smoking-induced emphysema which is centrilobular and affects the upper lobes ).
- 2. Chronic Obstructive Pulmonary Disease (COPD)
- Clinical Phenotypes
Chronic Bronchitis ("Blue Bloaters"): Defined clinically as productive cough for at least 3 consecutive months in 2 consecutive years . Characterized by mucus hypersecretion, cyanosis, hypoxemia, hypercapnia, pulmonary hypertension, and cor pulmonale (right heart failure with peripheral edema).
Emphysema ("Pink Puffers"): Defined pathologically as permanent enlargement of airspaces distal to terminal bronchioles with wall destruction. Characterized by severe dyspnea, hyperinflated chest (barrel chest), decreased breath sounds, pursed-lip breathing, and weight loss.
- GOLD Spirometric Staging (Based on Post-Bronchodilator F E V 1 FEV_1 FE V 1 % Predicted)
- GOLD 1 (Mild): F E V 1 ≥ 80 % FEV_1 \ge 80\% FE V 1 ≥ 80% predicted
- GOLD 2 (Moderate): 50 % ≤ F E V 1 < 80 % 50\% \le FEV_1 < 80\% 50% ≤ FE V 1 < 80% predicted
- GOLD 3 (Severe): 30 % ≤ F E V 1 < 50 % 30\% \le FEV_1 < 50\% 30% ≤ FE V 1 < 50% predicted
- GOLD 4 (Very Severe): F E V 1 < 30 % FEV_1 < 30\% FE V 1 < 30% predicted
- Pharmacotherapy & GOLD ABE Assessment Group Management
Group A (Low symptoms, 0-1 non-hospitalized exacerbations): Single bronchodilator (SABA, LABA, or LAMA).
Group B (High symptoms mMRC ≥ 2 \ge 2 ≥ 2 or CAT ≥ 10 \ge 10 ≥ 10 , 0-1 non-hospitalized exacerbations): Dual long-acting bronchodilator: LABA + LAMA (e.g., Tiotropium + Formoterol).
Group E (Exacerbators: ≥ 2 \ge 2 ≥ 2 moderate exacerbations OR ≥ 1 \ge 1 ≥ 1 leading to hospitalization): LABA + LAMA . Add Inhaled Corticosteroid (ICS) if blood eosinophils ≥ 300 cells/ μ L \ge 300 \text{ cells/}\mu\text{L} ≥ 300 cells/ μ L (forming Triple Therapy: LABA + LAMA + ICS).
Management of Acute COPD Exacerbation
Bronchodilators: Nebulized Short-Acting Beta-Agonist ( Salbutamol 2.5 − 5 mg 2.5-5 \text{ mg} 2.5 − 5 mg ) + Short-Acting Muscarinic Antagonist ( Ipratropium Bromide 0.5 mg 0.5 \text{ mg} 0.5 mg ).
Systemic Corticosteroids: Oral Prednisolone 40 mg 40 \text{ mg} 40 mg daily for 5 days (improves recovery and shortens hospital stay).
Controlled Oxygen Therapy: Administer via Venturi mask targeting S p O 2 SpO_2 Sp O 2 of 88–92% .
RATIONALE (UPSC CMS Focus): In chronic severe hypercapnia, the central respiratory center becomes desensitized to high P a C O 2 PaCO_2 P a C O 2 . Breathing is driven primarily by hypoxic drive detected by peripheral carotid bodies. Uncontrolled high-flow O 2 O_2 O 2 suppresses hypoxic drive and worsens V/Q mismatch via loss of hypoxic pulmonary vasoconstriction, precipitating severe hypercapnic coma ( P a C O 2 > 80 mmHg PaCO_2 >80 \text{ mmHg} P a C O 2 > 80 mmHg ).
Antibiotics: Indicated if 2 or more Anthonisen criteria are met (Increased Dyspnea, Increased Sputum Volume, Increased Sputum Purulence). Amoxicillin/Clavulanate or Macrolide for 5 days.
Non-Invasive Positive Pressure Ventilation (NIV / BiPAP): Indicated if acute hypercapnic respiratory acidosis ( p H < 7.35 pH < 7.35 p H < 7.35 and P a C O 2 > 45 mmHg PaCO_2 > 45 \text{ mmHg} P a C O 2 > 45 mmHg ) despite medical therapy.
- 3. Bronchial Asthma & GINA Guidelines
- Pathophysiology & Triggers
Chronic airway inflammation driven by IgE mast-cell degranulation, eosinophil recruitment, airway hyperresponsiveness, smooth muscle spasm, and subepithelial basement membrane thickening.
GINA Guidelines Treatment Strategy (Track 1 - Preferred)
Current Global Initiative for Asthma (GINA) guidelines strictly discourage SABA-only treatment due to increased mortality and risk of severe exacerbations.
Track 1 (Preferred Reliever): Uses Low-dose ICS-Formoterol as needed as the anti-inflammatory reliever (AIR) across ALL steps.
Step 1-2: As-needed low-dose ICS-Formoterol alone.
Step 3: Low-dose maintenance ICS-Formoterol + as-needed low-dose ICS-Formoterol (MART - Maintenance and Reliever Therapy).
Step 4: Medium-dose maintenance ICS-Formoterol + as-needed ICS-Formoterol.
Step 5: High-dose maintenance ICS-Formoterol + Add-on LAMA (Tiotropium) / Biologic agents (Omalizumab - anti-IgE, Mepolizumab - anti-IL5).
Acute Severe Asthma (Status Asthmaticus) Emergency Management
Clinical Severity Red Flags: Inability to complete sentences in one breath, Silent chest (absence of wheezing due to severe lack of airflow), Cyanosis, Bradycardia, Exhaustion, P E F R < 33 % PEFR <33\% PEFR < 33% predicted.
Critical Blood Gas Sign: A normal ( P a C O 2 ≈ 40 mmHg PaCO_2 \approx 40 \text{ mmHg} P a C O 2 ≈ 40 mmHg ) or elevated ( P a C O 2 > 45 mmHg PaCO_2 >45 \text{ mmHg} P a C O 2 > 45 mmHg ) level in a hyperventilating asthmatic patient is a dangerous sign of respiratory muscle fatigue and impending respiratory arrest (normally P a C O 2 PaCO_2 P a C O 2 should be low ≈ 25 − 30 mmHg \approx 25-30 \text{ mmHg} ≈ 25 − 30 mmHg due to hyperventilation).
Treatment: High-flow O 2 O_2 O 2 (target S p O 2 SpO_2 Sp O 2 93-95%), Continuous nebulized Salbutamol + Ipratropium, IV Hydrocortisone 200 mg 200 \text{ mg} 200 mg or Oral Prednisolone 50 mg 50 \text{ mg} 50 mg , single dose IV Magnesium Sulfate 2 g 2 \text{ g} 2 g over 20 minutes for severe refractory obstruction.
- 4. Acute Pulmonary Embolism (PE)
- Pathophysiology & Virchow's Triad
PE results from thrombi originating from deep vein thrombosis (DVT) of the lower extremities embolizing into the pulmonary arterial bed. Driven by Virchow's Triad: 1) Stasis, 2) Endothelial Injury, 3) Hypercoagulability.
Clinical Presentation
Sudden-onset dyspnea (most common symptom ~85%), pleuritic chest pain, tachypnea (>20/min), tachycardia (>100 bpm), hemoptysis, leg swelling (DVT), syncope (indicates massive PE).
Diagnostic Workup & Wells Score
- Wells Criteria for PE Score Points
- Clinical signs and symptoms of DVT +3.0
- PE is #1 diagnosis or equal to alternative diagnosis +3.0
- Heart rate > 100 beats/min >100 \text{ beats/min} > 100 beats/min +1.5
- Immobilization ≥ 3 \ge 3 ≥ 3 consecutive days or surgery in past 4 weeks +1.5
- Previous objectively diagnosed PE or DVT +1.5
- Hemoptysis +1.0
- Malignancy (treatment within 6 months or palliative) +1.0
Wells Score Triage:
PE Unlikely ( ≤ 4.0 \le 4.0 ≤ 4.0 points): Order High-Sensitivity D-Dimer . If negative ( < 500 ng/mL <500 \text{ ng/mL} < 500 ng/mL ), PE is ruled out without imaging (high negative predictive value). If positive, proceed to CTPA.
PE Likely ( > 4.0 >4.0 > 4.0 points): Proceed directly to CT Pulmonary Angiography (CTPA) (Gold Standard diagnostic imaging test).
Diagnostic Pearls:
V/Q Scanning: Indicated when CTPA is contraindicated (severe renal failure, IV contrast allergy, pregnancy).
ECG Findings: Most common finding is Sinus Tachycardia . Classic but rare sign is the S1Q3T3 pattern (McGinn-White sign) : Deep S wave in lead I, Q wave in lead III, Inverted T wave in lead III (<20% of cases). Right axis deviation and incomplete/complete RBBB reflect acute right heart strain.
Treatment Protocol
Hemodynamically Unstable (Massive PE with Shock / SBP <90 mmHg):
Immediate Thrombolysis with IV Alteplase (tPA 100 mg over 2 hours) or Tenecteplase. Surgical embolectomy if thrombolysis is contraindicated.
Hemodynamically Stable (Submassive / Low Risk):
Immediate Anticoagulation : Low Molecular Weight Heparin ( Enoxaparin 1 mg/kg 1 \text{ mg/kg} 1 mg/kg SC bid) or Unfractionated Heparin (UFH) bridged to Direct Oral Anticoagulants ( Rivaroxaban 15 mg 15 \text{ mg} 15 mg bid for 3 weeks then 20 mg 20 \text{ mg} 20 mg daily, or Apixaban ) or Warfarin (target INR 2.0–3.0) for at least 3 to 6 months .